Stocks
AstraZeneca PLC Financial Statements (AZN) |
||||||||||
| AstraZeneca PLCsmart-lab.ru | % | 2021 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.12.2021 | 22.02.2022 | 31.12.2022 | 21.02.2023 | 20.02.2024 | 30.09.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 37 417 | 37 417 | 44 351 | 44 351 | 45 811 | 52 120 | |||
| Operating Income, bln rub | 1 056 | 1 056 | 3 757 | 3 757 | 8 193 | 11 031 | ||||
| EBITDA, bln rub | ? | 7 565 | 4 675 | 9 327 | 8 649 | 12 977 | 16 846 | |||
| Net profit, bln rub | ? | 112.0 | 112.0 | 3 288 | 3 288 | 5 955 | 7 462 | |||
| OCF, bln rub | ? | 5 963 | 5 963 | 9 808 | 9 808 | 10 345 | 12 358 | |||
| CAPEX, bln rub | ? | 2 200 | 2 200 | 2 571 | 2 571 | 3 778 | 4 299 | |||
| FCF, bln rub | ? | 3 763 | 3 763 | 7 237 | 7 237 | 6 567 | 8 059 | |||
| Dividend payout, bln rub | 3 856 | 3 856 | 4 364 | 4 364 | 4 481 | 4 643 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 3 443% | 3 443% | 132.7% | 132.7% | 75.2% | 62.2% | ||||
| OPEX, bln rub | 23 924 | 23 924 | 28 203 | 28 203 | 29 578 | 28 575 | ||||
| Cost of production, bln rub | 12 437 | 12 437 | 12 391 | 12 391 | 8 268 | 12 514 | ||||
| R&D, bln rub | 9 736 | 9 736 | 9 762 | 9 762 | 11 015 | 11 566 | ||||
| Interest expenses, bln rub | 1 300 | 1 300 | 1 346 | 1 346 | 1 589 | 1 756 | ||||
| Assets, bln rub | 105 363 | 105 363 | 96 483 | 96 483 | 101 119 | 104 922 | ||||
| Net Assets, bln rub | ? | 39 268 | 39 268 | 37 037 | 37 037 | 39 143 | 40 719 | |||
| Debt, bln rub | 30 781 | 30 781 | 29 232 | 29 232 | 28 622 | 31 562 | ||||
| Cash, bln rub | 6 398 | 6 398 | 6 405 | 6 405 | 5 860 | 4 930 | ||||
| Net debt, bln rub | 24 383 | 24 383 | 22 827 | 22 827 | 22 762 | 26 632 | ||||
| Ordinary share price, rub | 58.3 | 58.3 | 67.8 | 67.8 | 67.4 | 64.3 | ||||
| Number of ordinary shares, mln | 2 836 | 2 836 | 3 096 | 3 096 | 3 098 | 3 100 | ||||
| Market cap, bln rub | 165 197 | 165 197 | 209 909 | 209 909 | 208 650 | 199 330 | ||||
| EV, bln rub | ? | 189 580 | 189 580 | 232 736 | 232 736 | 231 412 | 225 962 | |||
| Book value, bln rub | -23 116 | -23 116 | -22 090 | -22 090 | -18 994 | -19 814 | ||||
| EPS, rub | ? | 0.04 | 0.04 | 1.06 | 1.06 | 1.92 | 2.41 | |||
| FCF/share, rub | 1.33 | 1.33 | 2.34 | 2.34 | 2.12 | 2.60 | ||||
| BV/share, rub | -8.15 | -8.15 | -7.14 | -7.14 | -6.13 | -6.39 | ||||
| EBITDA margin, % | ? | 20.2% | 12.5% | 21.0% | 19.5% | 28.3% | 32.3% | |||
| Net margin, % | ? | 0.30% | 0.30% | 7.41% | 7.41% | 13.0% | 14.3% | |||
| FCF yield, % | ? | 2.28% | 2.28% | 3.45% | 3.45% | 3.15% | 4.04% | |||
| ROE, % | ? | 0.29% | 0.29% | 8.88% | 8.88% | 15.2% | 18.3% | |||
| ROA, % | ? | 0.11% | 0.11% | 3.41% | 3.41% | 5.89% | 7.11% | |||
| P/E | ? | 1 475 | 1 475 | 63.8 | 63.8 | 35.0 | 26.7 | |||
| P/FCF | 43.9 | 43.9 | 29.0 | 29.0 | 31.8 | 24.7 | ||||
| P/S | ? | 4.42 | 4.42 | 4.73 | 4.73 | 4.55 | 3.82 | |||
| P/BV | ? | -7.15 | -7.15 | -9.50 | -9.50 | -11.0 | -10.1 | |||
| EV/EBITDA | ? | 25.1 | 40.6 | 25.0 | 26.9 | 17.8 | 13.4 | |||
| Debt/EBITDA | 3.22 | 5.22 | 2.45 | 2.64 | 1.75 | 1.58 | ||||
| R&D/CAPEX, % | 442.5% | 442.5% | 379.7% | 379.7% | 291.6% | 269.0% | ||||
| CAPEX/Revenue, % | 5.88% | 5.88% | 5.80% | 5.80% | 8.25% | 8.25% | ||||
| AstraZeneca PLC shareholders | ||||||||||
